Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia

Journal of Human Hypertension volume 26, pages 388–395 (2012)Cite this article

Abstract

Dyslipidaemia is often associated with hypertension, and many clinical trials have shown that lipid-lowering therapy and strict blood pressure (BP) control are important for preventing cardiovascular disease (CVD). However, few reports describe the effect of statins on CVD occurrence in relation to long-term BP control. In the present analysis, we investigated the effects of baseline BP and follow-up BP control on the occurrence of CVD in patients enrolled in the MEGA Study. We investigated whether BP values provide more accurate prediction of the occurrence of CVD, including cerebrovascular disease/transischemic attack (CVA/TIA), and the effect of pravastatin on CVA/TIA. The risk for CVA/TIA and other CVD increased significantly (P⩽0.001) as the severity of hypertension increased. In contrast, pravastatin reduced the onset of CVA/TIA, regardless of the BP controlled. The mean BP was a more accurate predictor of CVD than a one-time BP value. In patients with mild-to-moderate dyslipidaemia, elevated BP increases the risk for CVA/TIA and other CVD, and rigorous BP control was important for preventing CVD, in particular CVA/TIA. The 12-month mean BP is useful to avoid attenuation to determine the association between CVD and BP. Pravastatin prevented CVA/TIA, regardless of BP controlled.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. Stokes J III, Kannel WB, Wolf PA, Cupples LA, D’Agostino RB . The relative importance of selected risk factors for various manifestations of cardiovascular disease among men and women from 35 to 64 years old: 30 years of follow-up in the Framingham Study. Circulation 1987; 75: V65–V73.

    PubMed  Google Scholar 

  2. Franklin SS, Gustin W IV, Wong ND, Larson MG, Weber MA, Kannel WB et al. Hemodynamic patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997; 96: 308–315.

    Article  CAS  Google Scholar 

  3. Kannel WB . Risk stratification in hypertension: new insights from the Framingham Study. Am J Hypertens 2000; 13: 3S–10S.

    Article  CAS  Google Scholar 

  4. Stamler J, Dyer AR, Shekelle RB, Neaton J, Stamler R . Relationship of baseline major risk factors to coronary and all-cause mortality, and to longevity: findings from long-term follow-up of Chicago cohorts. Cardiology 1993; 82: 191–222.

    Article  CAS  Google Scholar 

  5. Arima H, Tanizaki Y, Kiyohara Y, Tsuchihashi T, Kato I, Kubo M et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama Study. Arch Intern Med 2003; 163: 361–366.

    Article  Google Scholar 

  6. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R . Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

    Article  Google Scholar 

  7. Kannel WB, Dawber TR, Kagen A, Revotskie N, Stokes J III . Factors of risk in the development of coronary heart disease – six year follow-up experience: the Framingham Study. Ann Intern Med 1961; 55: 33–50.

    Article  CAS  Google Scholar 

  8. Satoh H, Nishino T, Tomita K, Saijo Y, Kishi R, Tsutsui H . Risk factors and the incidence of coronary artery disease in young middle-aged Japanese men: results from a 10-year cohort study. Intern Med 2006; 45: 235–239.

    Article  Google Scholar 

  9. Okamura T, Nakamura K, Kanda H, Hayakawa T, Hozawa A, Murakami Y et al. Effect of combined cardiovascular risk factors on individual and population medical expenditures: a 10-year cohort study of national health insurance in a Japanese population. Circ J 2007; 71: 807–813.

    Article  Google Scholar 

  10. Ishikawa T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T et al. The relationship between the effect of pravastatin and risk factors for coronary heart disease in Japanese patients with hypercholesterolemia. Circ J 2008; 72: 1576–1582.

    Article  CAS  Google Scholar 

  11. Uchiyama S, Nakaya N, Mizuno K, Ohashi Y, Tajima N, Kushiro T et al. Risk factors for stroke and lipid-lowering effect of pravastatin on the risk of stroke in Japanese patients with hypercholesterolemia: analysis of data from the MEGA Study, a large randomized controlled trial. J Neurol Sci 2009; 284: 72–76.

    Article  CAS  Google Scholar 

  12. Kushiro T, Mizuno K, Nakaya N, Ohashi Y, Tajima N, Teramoto T et al. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the management of elevated cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study. Hypertension 2009; 53: 135–141.

    Article  CAS  Google Scholar 

  13. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr et al. and The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure The JNC 7 report. JAMA 2003; 289: 2560–2572.

    Article  CAS  Google Scholar 

  14. Whitworth JA . 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–1992.

    Article  Google Scholar 

  15. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105–1187.

    Article  CAS  Google Scholar 

  16. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M et al. The Japanese society of hypertension guidelines for the management of hypertension (JSH 2009). Hypertens Res 2009; 32: 3–107.

    CAS  PubMed  Google Scholar 

  17. Prentice RL . Covariate measurement errors and parameter estimation in a failure time regression model. Biometrika 1982; 69: 331–342.

    Article  Google Scholar 

  18. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Group. Design and baseline characteristics of a study of primary prevention of coronary events with pravastatin among Japanese with mildly elevated cholesterol levels. Circ J 2004; 68: 860–867.

    Article  Google Scholar 

  19. Friedewald WT, Levy RI, Fredrickson DS . Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

    CAS  Google Scholar 

  20. Grundy SM, Bilheimer D, Chait A, Clark LT, Denke M, Havel RJ et al. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269: 3015–3023.

    Article  Google Scholar 

  21. Mizuno K, Nakaya N, Ohashi Y, Tajima N, Kushiro T, Teramoto T et al. Usefulness of pravastatin in primary prevention of cardiovascular events in women: analysis of the management of elevated cholesterol in the primary prevention group of adult Japanese (MEGA Study). Circulation 2008; 117: 494–502.

    Article  CAS  Google Scholar 

  22. Tajima N, Kurata H, Nakaya N, Mizuno K, Ohashi Y, Kushiro T et al. Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolaemic patients with impaired fasting glucose or diabetes: diabetes subanalysis of the management of elevated cholesterol in the primary prevention group of Adult Japanese (MEGA) Study. Atherosclerosis 2008; 199: 455–462.

    Article  CAS  Google Scholar 

  23. Cherry SB, Benner JS, Hussein MA, Tang SS, Nichol MB . The clinical and economic burden of nonadherence with antihypertensive and lipid-lowering therapy in hypertensive patients. Value Health 2009; 12: 489–497.

    Article  Google Scholar 

  24. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J et al. Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774.

    Article  CAS  Google Scholar 

  25. Keenan K, Hayen A, Neal BC, Irwig L . Long term monitoring in patients receiving treatment to lower blood pressure: analysis of data from placebo controlled randomised controlled trial. BMJ 2009; 338: b1492; doi: 10.1136/bmj.b1492.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial–Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003; 361: 1149–1158.

    Article  CAS  Google Scholar 

  27. Sever P, Dahlöf B, Poulter N, Wedel H, Beevers G, Caulfield M et al. Potential synergy between lipid-lowering and blood-pressure-lowering in the Anglo-Scandinavian cardiac outcomes trial. Eur Heart J 2006; 27: 2982–2988.

    Article  CAS  Google Scholar 

  28. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7–22.

    Article  Google Scholar 

  29. Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575–1585.

    Article  Google Scholar 

  30. Wierzbicki AS, Mikhailidis DP, Reynolds TM . More on PROSPER. Lancet 2003; 361: 1135–1136.

    Article  Google Scholar 

  31. Murakami Y, Hozawa A, Okamura T, Ueshima H . Relation of blood pressure and all-cause mortality in 180,000 Japanese participants: pooled analysis of 13 cohort studies. Hypertension 2008; 51: 1483–1491.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The MEGA Study Publication Committee controlled the writing of this manuscript, and all analyses were conducted in the MEGA Study Data Centre. Research funds were provided by Sankyo Co Ltd, now Daiichi Sanky Co Ltd. We thank all the study participants, physicians, co-medical staff and coworkers.

Clinical trial registration: This trial is registered at ClinicalTrials.gov, number NCT00211705. http://www.clinicaltrials.gov/ct/show/NCT00211705;jsessionid=9140B4E3B2E305477D0A1323922BA330?order=1.

Author information

Authors and Affiliations

  1. Health Planning Center, Nihon University School of Medicine, Tokyo, Japan

    T Kushiro

  2. Department of Internal Medicine, Nippon Medical School, Tokyo, Japan

    K Mizuno

  3. Department of Internal Medicine, Nakaya Clinic, Tokyo, Japan

    N Nakaya

  4. Department of Biostatistics/Epidemiology and Preventive Health Sciences, University of Tokyo, Tokyo, Japan

    Y Ohashi

  5. Department of Internal Medicine, Teikyo University School of Medicine, Tokyo, Japan

    T Teramoto

  6. Nagoya City University Graduate School of Medical Science, Tokyo, Japan

    S Yokoyama

  7. Otaru Kyoukai Hospital, Tokyo, Japan

    S Kakinoki

  8. Mitsukoshi Health and Welfare Foundation, Tokyo, Japan

    H Nakamura

Authors
  1. T Kushiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. N Nakaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Y Ohashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. T Teramoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S Yokoyama
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S Kakinoki
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. H Nakamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Consortia

for the MEGA Study Group

Corresponding author

Correspondence to T Kushiro.

Ethics declarations

Competing interests

The following authors have received consultant fees, travel fees, lecture fees and/or research grants from the following companies: Dr Mizuno, Sankyo; Dr Nakaya, Sankyo, Banyu, Novartis, Pfizer, Kowa, AstraZeneca; Dr Ohashi, Sankyo, Banyu, Novartis, Astellas, Pfizer, Kowa, AstraZeneca; Dr Kushiro, Sankyo; Dr Teramoto, Sankyo, Banyu, Novartis, Astellas, Pfizer, Kowa, AstraZeneca, Shionogi; Dr Nakamura, Sankyo, Banyu. Dr Yokoyama and Dr Kakinoki declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kushiro, T., Mizuno, K., Nakaya, N. et al. Blood pressure control status and effects of pravastatin on cardiovascular events occurrence in patients with dyslipidaemia. J Hum Hypertens 26, 388–395 (2012). https://doi.org/10.1038/jhh.2011.49

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2011.49

Keywords

This article is cited by

Search

Advanced search

Quick links